Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity

Completed · Phase 2

Conditions studied: Stroke, Muscle Spasticity

In brief

The purpose of this study is to evaluate the safety of repeated doses of Botulinum Toxin Type A for the treatment of focal upper limb poststroke spasticity

Key facts

Study ID

NCT00651729

Run by

Allergan

People needed

279

Starts

2003-04-01

Expected to finish

2004-12-01

Last updated by the study team

2008-05-28

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Medically stable poststroke patients with spastic muscles in the upper limb

You may not qualify if…

• Stroke within 6 months of study enrollment
• Previous therapy with Botulinum Toxin Type A for treatment of any condition prior to 4 months of enrollment, for treatment of any condition prior to 01 January 1998

Where it is running

• Study site — Indianapolis, Indiana, United States
• Study site — Vancouver, British Columbia, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.